Bill An­der­son to step down as Roche phar­ma chief by mon­th's end

3 years ago
People
Pharma

#ASH22 roundup: CSL shows two years of da­ta in $3.5M he­mo­phil­ia gene ther­a­py; Syn­dax shows 30% CR rate from March ...

3 years ago
R&D

Up­dat­ed: Hori­zon's $28B sale to Am­gen was kicked off by Sanofi's in­ter­est

3 years ago
Deals
Pharma

Up­dat­ed: Am­gen in ad­vanced talks for Hori­zon, WSJ re­ports; Sanofi pulls out

3 years ago
Deals
Pharma

#ASH22: Re­gen­eron re­veals its first PhII da­ta in con­test­ed CD20xC3 bis­pe­cif­ic race

3 years ago
R&D
Pharma

#ASH22: Bris­tol My­ers re­ports next-gen CAR-T da­ta as ri­val’s bis­pe­cif­ic heads to FDA, and gives al­nuc­tam­ab an­oth­er ...

3 years ago
R&D
Cell/Gene Tx

#ASH22: Lil­ly’s Loxo spells out BTK da­ta as it eyes BeiGene, Ab­b­Vie/J&J and As­traZeneca

3 years ago
R&D

#ASH22: 'Not so sur­pris­ing': With lack of dura­bil­i­ty, Af­fimed scraps monother­a­py plans in fa­vor of NK cell com­bo

3 years ago
R&D

#ASH22: J&J touts first PhII re­sults of next-gen mul­ti­ple myelo­ma an­ti­body

3 years ago
R&D
Pharma

#ASH22: Ku­ra’s menin in­hibitor heads to PhII in sub­set of acute myeloid leukemia with mixed da­ta

3 years ago
R&D

#ASH22: Adicet touts longer-term CR da­ta af­ter AS­CO win

3 years ago
R&D

End­points hon­ors 20 women lead­ers; Ver­tex teams up with neigh­bor; Pfiz­er ri­val im­press­es; and more

3 years ago
Weekly

Val­isure in the hot seat: New Form 483 over a 2021 in­spec­tion as CEO fires back

3 years ago
Pharma
FDA+

Mov­ing to the em­ploy­er side of health­care, Mark Cuban's Cost Plus Drugs part­ners with a PBM

3 years ago
Pharma

WIB22: Am­ber Salz­man had few op­tions when her son was di­ag­nosed with a rare ge­net­ic dis­ease. So she cre­at­ed a bet­ter ...

3 years ago
People
Special

FDA re­view­ers head back to White Oak in 2023, with lead­er­ship look­ing to ap­pease a new Con­gress

3 years ago
FDA+

Ahead of ad­comm, FDA rais­es un­cer­tain­ties on ben­e­fit-risk pro­file of Cy­to­ki­net­ic­s' po­ten­tial heart drug

3 years ago
FDA+

Bags of shred­ded docs: In­di­an drug­mak­er Lupin hand­ed a Form 483 by FDA in­spec­tors

3 years ago
Pharma
FDA+

Bro­ken promis­es? FDA needs more pow­er to re­move drugs from mar­ket­place, JA­MA analy­sis finds

3 years ago
FDA+

Ab­b­Vie slapped with age dis­crim­i­na­tion law­suit, fol­low­ing oth­er phar­mas

3 years ago
Pharma
Law

Up­dat­ed: Gilead, Ar­cel­lx team up on an­ti-BC­MA CAR-T as biotech touts a 100% re­sponse rate at #ASH22

3 years ago
Deals
R&D

WIB22: Lead­ing NK cell re­searcher re­flects on roots in Iran, the UK and Texas

3 years ago
People
Special

Replimune looks to rope in $225M on the back of melanoma da­ta

3 years ago
Financing
R&D

Eras­ca delves fur­ther in­to RAS/MAPK with No­var­tis drug, prices $100M of­fer­ing

3 years ago
Financing
Deals
First page Previous page 416417418419420421422 Next page Last page
A service from the Financial Times